Aldevron is Biotechnology in United States that focus on gene editing business. Founded in 1998. They cover business area such as developer, biological product, provider, scientific service, research, clinical and diagnostic application, custom production, plasmid DNA, nucleic acid, protein, antibody, gene therapy, gene editing, academic and research institution, pharmaceutical and biotechnology company, novel treatment, indication, cancer, infectious disease, pediatric disorder, rare disease.
1998
( 26 years old in 2024 )
Gene Editing
-
4055 41st Avenue South
Fargo, ND 58104
United States
Private
developerbiological productproviderscientific serviceresearch, clinical and diagnostic applicationcustom productionplasmid DNAnucleic acidproteinantibodygene therapygene editingacademic and research institutionpharmaceutical and biotechnology companynovel treatmentindicationcancerinfectious diseasepediatric disorderrare disease
* We use standard office opening hours in near Aldevron's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Aldevron is Biotechnology business from United States that founded in 1998 (26 years old in 2024), Aldevron business is focusing on Gene Editing.
Aldevron headquarter office and corporate office address is located in 4055 41st Avenue South Fargo, ND 58104 United States.
Aldevron was founded in United States.
In 2024, Aldevron is currently focus on gene editing sector.
Above is snippet of Google Trends for "gene editing" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Aldevron, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
